Immix stock climbs 40% on in-licensing potential blood cancer therapy

Dec. 14, 2022 9:06 AM ETImmix Biopharma, Inc. (IMMX)By: Ravikash, SA News Editor1 Comment

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Analysing Test Samples. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


  • Immix Biopharma (NASDAQ:IMMX) said it in-licensed a BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
  • The company added that has formed a wholly-owned subsidiary called Nexcella to develop and potentially commercialize NXC-201.
  • The drug had shown about 85% overall response rate (ORR) and

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.